1098
Acknowledgements
We thank the Commonwealth Scholarship Commission, UK for a research studentship to A. N. Khan.
References
1. McCulloch, J.; Bullock, R.; Teesdale, G. M. In Excitatory Amino Acid Antagonists; Meldrum, B. S., Ed.; Blackwell Scientific
Publications: Oxford, 1991; pp. 287–326.
2. Collingridge, G. L.; Lester, R. A. Pharmacol. Rev. 1989, 40, 143–210.
3. Goodnow, R.; Konno, K.; Niwa, M.; Kallimopoulos, T.; Buknownik, R.; Lenares, D.; Nakanishi, K. Tetrahedron 1990, 46,
3267–3286.
4. Piek, T. Am. Chem. Soc., Symp. Series 1993, 524, 233–238.
5. Blagbrough, I. S.; Usherwood, P. N. R. Proc. Roy. Soc. Edin. 1992, 99B, 67–81.
6. Eldefrawi, A. T.; Elderfrawi, E. E.; Konno, K.; Mansour, N. A.; Nakanishi, K.; Oltz, E.; Usherwood, P. N. R. Proc. Natl.
Acad. Sci. USA 1988, 85, 4910–4913.
7. Choi, S. K.; Nakanishi, K.; Usherwood, P. N. R. Tetrahedron 1993, 49, 5777–5790.
8. Choi, S. K.; Goodnow, R. A.; Kalivretenos, A.; Chiles, G. W.; Fushiya, K.; Nakanishi, K. Tetrahedron 1992, 48, 4793–4822.
9. Hidai, Y.; Kan, T.; Fukuyama, T. Tetrahedron Lett. 1999, 40, 4711–4714.
10. Blagbrough, I. S.; Moya, E. Tetrahedron Lett. 1994, 35, 2057–2060.
11. Marsh, I. R.; Bradley, M. J. Chem. Soc., Chem. Commun. 1996, 941–942.
12. Nefzi, A.; Ostresh, J. M.; Houghten, R. A. Tetrahedron 1999, 55, 335–344.
13. Carrington, S.; Renault, J.; Tomasi, S.; Corbel, J.-C.; Uriac, P.; Blagbrough, I. S. Chem. Commun. 1999, 1341–1342.
14. Bycroft, B. W.; Chan, W. C.; Hone, N. D.; Millington, S.; Nash, I. A. J. Am. Chem. Soc. 1994, 116, 7415–7416.
15. Nash, I. A.; Bycroft, B. W.; Chan, W. C. Tetrahedron Lett. 1996, 37, 2625–2628.
16. Bycroft, B. W.; Chan, W. C.; Chhabra, S. R.; Hone, N. D. J. Chem. Soc., Chem. Commun. 1993, 778–779.
17. Chhabra, S. R.; Hothi, B.; Evans, D. J.; White, P. D.; Bycroft, B. W.; Chan, W. C. Tetrahedron Lett. 1998, 39, 1603–1606.
18. Chhabra, S. R.; Khan, A. N.; Bycroft, B. W. Tetrahedron Lett. 1998, 39, 3585–3588.
19. N4,N9-bis-Boc-N1,N12-bis-Dde spermine 4: m.p. 94–96oC; Rf 0.5 (SiO2, 1% MeOH/EtOAc). Found: C, 65.56; H, 9.23; N,
7.65. C40H66N4O8 requires: C, 65.72; H, 9.10; N, 7.67%; δH (250 MHz, CDCl3) 1.03 (12H, s, ring 2×Me2), 1.43 (18H,
s, 2×Me3), 1.55 (4H, s, 6, 7-(CH2)2), 1.84–199 (4H, m, 2, 11-(CH2)2), 2.36 (8H, s, ring 4×CH2), 2.55 (6H, s, 2×_CMe),
3.18–3.23 (4H, m, 5, 8-(CH2)2), 3.25–3.34 (4H, m, 3,10-(CH2)2), 3.35–3.44 (4H, m, 1,12-(CH2)2), 13.49 (2H, s, 2×NH);
δc (62.9 MHz, CDCl3) 18.25 (2, 6, 7, 11-CH2), 28.62 (ring Me2), 28.78 (Me3), 30.46 (ring CMe2), 41.47 (_CCH3), 44.68
(2×ring CH2), 53.20 (1, 3, 5, 8, 10, 12-CH2), 80.11 (Me3C_O), 108.25 (alkene C), 155.82 (_C-NH), 173.86 (carbamate
C_O), 198.26 (ring C_O). ES-MS m/z 731.6 (M+H, C40H66N4O8 requires: m/z 730.96).
20. RPHPLC was performed using a Hypersil Pep-100 C18 column (4.6×150 cm) at a constant flow rate of 1.2 ml min−1
Mobile phase: (A) 0.06% TFA(aq) and (B) 0.06% TFA in 90% MeCN(aq); gradient: 20 to 100% B in 30 min linearly.
21. Brown, E. G.; Nuss, J. M. Tetrahedron Lett. 1997, 38, 8457–8460 and the references cited therein.
.
22. 3-Fmoc-Aminopropanal was prepared from N-Fmoc-β-alanine by its conversion to N-methoxy-N-methyl-3-(Fmoc-
amino)propionamide (80%) followed by reduction with LiAlH4 in dry diethyl ether (76%). (Nahm, S.; Weinreb, S. M.
Tetrahedron Lett. 1981, 22, 3815–3818).
23. Chhabra, S. R.; Khan, A. N.; Bycroft, B. W. Tetrahedron Lett. 2000, 41, 1099–1102.